 GAINESVILLE, Fla.--BUSINESS WIRE--Cyclo Therapeutics, Inc. Nasdaq: CYTH Cyclo Therapeutics or the Company, a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced that it has posted its protocol on and is preparing to commence its pivotal Phase 3 study evaluating Trappsol CycloTM, a proprietary formulation of hydroxypropyl beta cyclode 